PreMD seeks to boost US market potential for skin cholesterol test:
This article was originally published in Clinica
Executive Summary
PreMD has filed a 510(k) marketing application with the US FDA to expanded the indications for its point-of-care (POC) skin cholesterol test Prevu(x), to include it use in assessing cardiovascular disease risk in individuals without known or suspected disease. "An expanded claim could dramatically increase the market potential of Prevu(x) POC," said Brent Norton, the Toronto, Canada firm's president and CEO. It would make the product "the first cost-effective, noninvasive test on the market to help assess carotid wall thickness and the presence of carotid plaques in patients without known coronary artery disease, cerebrovascular disease or peripheral artery disease", claimed the company. Carotid wall thickness and carotid plaques are established markers for future heart attacks and strokes. "Our discussions with potential marketing partners are advancing," said Dr Norton.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.